{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:28:07Z","timestamp":1769041687795,"version":"3.49.0"},"reference-count":40,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"DOI":"10.13039\/501100004944","name":"Naresuan University","doi-asserted-by":"publisher","award":["PHD\/0021\/2558"],"award-info":[{"award-number":["PHD\/0021\/2558"]}],"id":[{"id":"10.13039\/501100004944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2019,10,3]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Amphotericin B (AmB) is important for the treatment of systemic fungal infections. Nowadays, only intravenous administration (IV) of AmB has been available due to its low aqueous solubility. Two forms of AmB are available. The first is Fungizone\u00ae, a mixture of AmB and sodium deoxcycholate that produces severe nephrotoxicity. The second are lipid-based formulations that reduce nephrotoxicity, but they are costly and require higher dose than Fungizone\u00ae. Thus, a cheaper delivery system with reduced AmB toxicity is required.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>To develop and characterize AmB loaded-nanostructured lipid carriers (AmB-loaded NLCs) for IV administration to reduce AmB toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>AmB-loaded NLCs with different solid lipids were prepared by the high-pressure homogenization technique. Their physicochemical properties and the drug release profile were examined. The molecular structure of AmB, antifungal and hemolysis activities of developed AmB-loaded NLCs were also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>AmB-loaded NLCs ~110 to ~140 nm in diameter were successfully produced with a zeta potential of ~-19 mV and entrapment efficiency of ~75%. In vitro release showed fast release characteristics. AmB-loaded NLCs could reduce the AmB molecular aggregation as evident from the absorbance ratio of the first to the fourth peak showing a partial aggregation of AmB. This result suggested that AmB-loaded NLCs could offer less nephrotoxicity compared to Fungizone\u00ae. In vitro antifungal activity of AmB-loaded NLCs showed a minimum inhibitory concentration of 0.25 \u00b5gmL-1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>AmB-loaded NLCs present high potential carriers for effective IV treatment with prolonged circulation time and reduced toxicity.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1567201816666190729145223","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T10:55:03Z","timestamp":1564484103000},"page":"645-653","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Amphotericin B Loaded Nanostructured Lipid Carriers for Parenteral Delivery: Characterization, Antifungal and In vitro Toxicity Assessment"],"prefix":"10.2174","volume":"16","author":[{"given":"Pataranapa","family":"Nimtrakul","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok 6500, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waree","family":"Tiyaboonchai","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok 6500, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supaporn","family":"Lamlertthon","sequence":"additional","affiliation":[{"name":"Centre of excellence in Fungal Research and Department of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Phitsanulok 6500, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","volume":"73","author":"Hamill R.J.","year":"2013","unstructured":"Hamill R.J.; Amphotericin B.; Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 2013,73(9),919-934","journal-title":"Drugs"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ijpharm.2009.01.003","volume":"372","author":"Wasan E.K.","year":"2009","unstructured":"Wasan E.K.; Bartlett K.; Gershkovich P.; Sivak O.; Banno B.; Wong Z.; Gagnon J.; Gates B.; Leon C.G.; Wasan K.M.; Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm 2009,372(1-2),76-84","journal-title":"Int J Pharm"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1681\/ASN.V62154","volume":"6","author":"Sawaya B.P.","year":"1995","unstructured":"Sawaya B.P.; Briggs J.P.; Schnermann J.; Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995,6(2),154-164","journal-title":"J Am Soc Nephrol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1086\/376634","volume":"37","author":"Ostrosky-Zeichner L.","year":"2003","unstructured":"Ostrosky-Zeichner L.; Marr K.A.; Rex J.H.; Cohen S.H.; Cohen S.H.; Amphotericin B.; Amphotericin B: time for a new \u201cgold standard\u201d. Clin Infect Dis 2003,37(3),415-425","journal-title":"Clin Infect Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2165\/00002018-199005020-00003","volume":"5","author":"Sabra R.","year":"1990","unstructured":"Sabra R.; Branch R.A.; Amphotericin B nephrotoxicity. Drug Saf 1990,5(2),94-108","journal-title":"Drug Saf"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1179\/joc.2000.12.6.463","volume":"12","author":"Fanos V.","year":"2000","unstructured":"Fanos V.; Cataldi L.; Amphotericin B-induced nephrotoxicity: a review. J Chemother 2000,12(6),463-470","journal-title":"J Chemother"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","volume":"26","author":"Laniado-Labor\u00edn R.","year":"2009","unstructured":"Laniado-Labor\u00edn R.; Cabrales-Vargas M.N.; Amphotericin B.; Amphotericin B: side effects and toxicity. Rev Iberoam Micol 2009,26(4),223-227","journal-title":"Rev Iberoam Micol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1081\/DDC-120039793","volume":"30","author":"Risovic V.","year":"2004","unstructured":"Risovic V.; Sachs-Barrable K.; Boyd M.; Wasan K.M.; Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B. Drug Dev Ind Pharm 2004,30(7),767-774","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jac\/49.suppl_1.31","volume":"49","author":"Dupont B.","year":"2002","unstructured":"Dupont B.; Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002,49(Suppl. 1),31-36","journal-title":"J Antimicrob Chemother"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijpharm.2006.08.013","volume":"329","author":"Tiyaboonchai W.","year":"2007","unstructured":"Tiyaboonchai W.; Limpeanchob N.; Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles. Int J Pharm 2007,329(1-2),142-149","journal-title":"Int J Pharm"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1248\/yakushi.128.269","volume":"128","author":"Rawat M.","year":"2008","unstructured":"Rawat M.; Singh D.; Saraf S.; Saraf S.; Lipid carriers: a versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi 2008,128(2),269-280","journal-title":"Yakugaku Zasshi"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.10.003","volume":"366","author":"Pardeike J.","year":"2009","unstructured":"Pardeike J.; Hommoss A.; M\u00fcller R.H.; Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009,366(1-2),170-184","journal-title":"Int J Pharm"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2006.08.013","volume":"116","author":"des Rieux A.","year":"2006","unstructured":"des Rieux A.; Fievez V.; Garinot M.; Schneider Y-J.; Pr\u00e9at V.; Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006,116(1),1-27","journal-title":"J Control Release"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.colsurfb.2013.12.012","volume":"116","author":"Ranpise N.S.","year":"2014","unstructured":"Ranpise N.S.; Korabu S.S.; Ghodake V.N.; Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces 2014,116,81-87","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.15171\/apb.2015.043","volume":"5","author":"Naseri N.","year":"2015","unstructured":"Naseri N.; Valizadeh H.; Zakeri-Milani P.; Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull 2015,5(3),305-313","journal-title":"Adv Pharm Bull"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0927-7757(97)00267-7","volume":"140","author":"McNeil-Watson F.","year":"1998","unstructured":"McNeil-Watson F.; Tscharnuter W.; Miller J.; A new instrument for the measurement of very small electrophoretic mobilities using phase analysis light scattering (PALS). Colloids Surf A Physicochem Eng Asp 1998,140(1),53-57","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"10183","DOI":"10.1166\/jnn.2015.11694","volume":"15","author":"Casa D.M.","year":"2015","unstructured":"Casa D.M.; Karam T.K.; Alves, Ade.C.; Zgoda, A.A.; Khalil, N.M.; Mainardes, R.M. Bovine serum albumin nanoparticles containing amphotericin B: characterization, cytotoxicity and in vitro antifungal evaluation. J Nanosci Nanotechnol 2015,15(12),10183-10188","journal-title":"J Nanosci Nanotechnol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.22159\/ijap.2018v10i2.24738","volume":"10","author":"Niamprem P.","year":"2018","unstructured":"Niamprem P.; Srinivas S.; Tiyaboonchai W.; Development and characterization of indomethacin-loaded mucoadhesive nanostructured lipid carriers for topical ocular delivery. Int J Appl Biol Pharm 2018,10(2),91-96","journal-title":"Int J Appl Biol Pharm"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1007\/s11095-012-0958-3","volume":"30","author":"Kulkarni S.A.","year":"2013","unstructured":"Kulkarni S.A.; Feng S-S.; Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res 2013,30(10),2512-2522","journal-title":"Pharm Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4236\/jbnb.2016.72011","volume":"7","author":"Sadat S.M.A.","year":"2016","unstructured":"Sadat S.M.A.; Jahan S.T.; Haddadi A.; Effects of Size and Surface Charge of Polymeric Nanoparticles on in vitro and in vivo Applications. J Biomater Nanobiotechnol 2016,7,91-108","journal-title":"J Biomater Nanobiotechnol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1016\/j.biomaterials.2004.07.050","volume":"26","author":"Win K.Y.","year":"2005","unstructured":"Win K.Y.; Feng S-S.; Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005,26(15),2713-2722","journal-title":"Biomaterials"},{"key":"ref=22","first-page":"265","volume":"12","author":"Honary S.","year":"2013","unstructured":"Honary S.; Zahir F.; Effect of zeta potential on the properties of nano-drug delivery systems - a review (Part 2). Trop J Pharm Res 2013,12(2),265-273","journal-title":"Trop J Pharm Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.biomaterials.2006.12.002","volume":"28","author":"Unger F.","year":"2007","unstructured":"Unger F.; Wittmar M.; Kissel T.; Branched polyesters based on poly[vinyl-3-(dialkylamino)alkylcarbamate-co-vinyl acetate-co-vinyl alcohol]-graft-poly(d,l-lactide-co-glycolide): effects of polymer structure on cytotoxicity. Biomaterials 2007,28(9),1610-1619","journal-title":"Biomaterials"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/03639045.2016.1257020","volume":"43","author":"Chanburee S.","year":"2017","unstructured":"Chanburee S.; Tiyaboonchai W.; Mucoadhesive nanostructured lipid carriers (NLCs) as potential carriers for improving oral delivery of curcumin. Drug Dev Ind Pharm 2017,43(3),432-440","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.colsurfb.2010.07.020","volume":"81","author":"Nayak A.P.","year":"2010","unstructured":"Nayak A.P.; Tiyaboonchai W.; Patankar S.; Madhusudhan B.; Souto E.B.; Curcuminoids-loaded lipid nanoparticles: novel approach towards malaria treatment. Colloids Surf B Biointerfaces 2010,81(1),263-273","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0378-5173(02)00180-1","volume":"242","author":"M\u00fcller R.H.","year":"2002","unstructured":"M\u00fcller R.H.; Radtke M.; Wissing S.A.; Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002,242(1-2),121-128","journal-title":"Int J Pharm"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","volume":"54","author":"M\u00fcller R.H.","year":"2002","unstructured":"M\u00fcller R.H.; Radtke M.; Wissing S.A.; Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002,54(Suppl. 1),S131-S155","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000180883","volume":"19","author":"Churchill D.N.","year":"1977","unstructured":"Churchill D.N.; Seely J.; Nephrotoxicity associated with combined gentamicin-amphotericin B therapy. Nephron 1977,19(3),176-181","journal-title":"Nephron"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/0005-2736(80)90074-7","volume":"599","author":"Bolard J.","year":"1980","unstructured":"Bolard J.; Seigneuret M.; Boudet G.; Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B: lipid state and cholesterol content dependence. Biochim Biophys Acta 1980,599(1),280-293","journal-title":"Biochim Biophys Acta"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0168-3659(02)00347-4","volume":"87","author":"Adams M.L.","year":"2003","unstructured":"Adams M.L.; Kwon G.S.; Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)-block-poly(N-hexyl-L-aspartamide)-acyl conjugate micelles: effects of acyl chain length. J Control Release 2003,87(1-3),23-32","journal-title":"J Control Release"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0009-3084(96)02652-7","volume":"85","author":"Barwicz J.","year":"1997","unstructured":"Barwicz J.; Tancr\u00e8de P.; The effect of aggregation state of amphotericin-B on its interactions with cholesterol- or ergosterol-containing phosphatidylcholine monolayers. Chem Phys Lipids 1997,85(2),145-155","journal-title":"Chem Phys Lipids"},{"key":"ref=32","first-page":"1769","volume":"10","author":"Zia Q.","year":"2015","unstructured":"Zia Q.; Khan A.A.; Swaleha Z.; Owais M.; Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: Preparation, characterization and in vitro potential against Candida albicans. Int J Nanomedicine 2015,10,1769-1790","journal-title":"Int J Nanomedicine"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1021\/jp110543g","volume":"115","author":"Gago\u015b M.","year":"2011","unstructured":"Gago\u015b M.; Arczewska M.; Influence of K+ and Na+ ions on the aggregation processes of antibiotic amphotericin B: electronic absorption and FTIR spectroscopic studies. J Phys Chem B 2011,115(12),3185-3192","journal-title":"J Phys Chem B"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1016\/S0006-3495(02)75326-5","volume":"83","author":"Huang W.","year":"2002","unstructured":"Huang W.; Zhang Z.; Han X.; Tang J.; Wang J.; Dong S.; Wang E.; Ion channel behavior of amphotericin B in sterol-free and cholesterol- or ergosterol-containing supported phosphatidylcholine bilayer model membranes investigated by electrochemistry and spectroscopy. Biophys J 2002,83(6),3245-3255","journal-title":"Biophys J"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s12272-001-2131-0","volume":"31","author":"Bang J-Y.","year":"2008","unstructured":"Bang J-Y.; Song C-E.; Kim C.; Park W-D.; Cho K-R.; Kim P-I.; Lee S-R.; Chung W-T.; Choi K-C.; Cytotoxicity of amphotericin B-incorporated polymeric micelles composed of poly(DL-lactide-co-glycolide)\/dextran graft copolymer. Arch Pharm Res 2008,31(11),1463-1469","journal-title":"Arch Pharm Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/mabi.200900387","volume":"10","author":"Falamarzian A.","year":"2010","unstructured":"Falamarzian A.; Lavasanifar A.; Chemical modification of hydrophobic block in poly(ethylene oxide) poly(caprolactone) based nanocarriers: effect on the solubilization and hemolytic activity of amphotericin B. Macromol Biosci 2010,10(6),648-656","journal-title":"Macromol Biosci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s11095-009-9841-2","volume":"26","author":"Italia J.L.","year":"2009","unstructured":"Italia J.L.; Yahya M.M.; Singh D.; Ravi Kumar M.N.V.; Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone. Pharm Res 2009,26(6),1324-1331","journal-title":"Pharm Res"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nchembio.1496","volume":"10","author":"Anderson T.M.","year":"2014","unstructured":"Anderson T.M.; Clay M.C.; Cioffi A.G.; Diaz K.A.; Hisao G.S.; Tuttle M.D.; Nieuwkoop A.J.; Comellas G.; Maryum N.; Wang S.; Uno B.E.; Wildeman E.L.; Gonen T.; Rienstra C.M.; Burke M.D.; Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol 2014,10(5),400-406","journal-title":"Nat Chem Biol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/10717544.2016.1228715","volume":"24","author":"Radwan M.A.","year":"2017","unstructured":"Radwan M.A.; AlQuadeib B.T.; \u0160iller L.; Wright M.C.; Horrocks B.; Oral administration of amphotericin B nanoparticles: antifungal activity, bioavailability and toxicity in rats. Drug Deliv 2017,24(1),40-50","journal-title":"Drug Deliv"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/02652049809006844","volume":"15","author":"Gulati M.","year":"1998","unstructured":"Gulati M.; Bajad S.; Singh S.; Ferdous A.J.; Singh M.; Development of liposomal amphotericin B formulation. J Microencapsul 1998,15(2),137-151","journal-title":"J Microencapsul"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/173922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T21:09:29Z","timestamp":1664053769000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/173922\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,3]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,10,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201816666190729145223","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}